Jan 25, 2024 · TARRYTOWN, N.Y. and PARIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug …

Learn more about DUPIXENT® (dupilumab), the first FDA-approved biologic to treat eosinophilic esophagitis (EoE) in adult and pediatric patients aged 1 year and older who weigh at least 33lb …

Jun 27, 2024 · Dupilumab resulted in histologic remission in a significantly higher percentage of children with eosinophilic esophagitis than placebo. The higher-exposure dupilumab regimen also led to …

Dec 21, 2022 · Dupilumab, a fully human monoclonal antibody, blocks interleukin-4 and interleukin-13 signaling, which have key roles in eosinophilic esophagitis. We conducted a three-part, phase 3 trial …

Sep 11, 2025 · A meta-analysis of five retrospective studies encompassing 209 subjects with EoE treated with Dupixent showed that around 90% of patients experienced symptom improvement. The …

The Disease Eosinophilic esophagitis (EoE) is a long-term, inflammatory disease of the esophagus, affecting children and adults In children, it causes symptoms such as vomiting, pain, and difficulty …

Jan 25, 2024 · 11 years, weighing at least 15 kg, with eosinophilic esophagitis (EoE). Dupixent is now the first and only medicine approved in the U.S. specifically indicated to treat these patients. This …

Feb 21, 2024 · The US Food and Drug Administration approvals of dupilumab (Dupixent, Regeneron/Sanofi) for adults and children with eosinophilic esophagitis (EoE) affirmed the safety and …

Among subjects with EoE, there were no reports of conjunctivitis and keratitis in the DUPIXENT group in placebo-controlled trials. In the 36-week active treatment extension period of Study EoE-2 Part B, …

Dec 11, 2024 · Intention-to-treat analysis applied. Funding: Sanofi and Regeneron Pharmaceuticals. Results: Overall, 168 (74%) patients had previously used swallowed topical corticosteroids (tCs) for …